Latest Breaking News On - Shefali agarwal - Page 6 : comparemela.com

Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million

> Cash position of €17.9 million as of December 31, 2021 > Additional financing of €12 million subscribed by historical shareholders Invus and Financière de la Montagne in the form of the issuance

United statesFrance generalJulien miaraAcrotech biopharmaJudith grecietEmmanuel huynhArthur rouillOnxeo sa euronextRobertl colemanValerie leroyGustave roussyBryan giraudoInstitut curieGossamer bio incAudit committeeTrademark office

Onxeo S A : Onxeo Appoints Julien Miara as New Interim CEO

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative

France generalNicolas merigeauJulien miaraEmmanuel huynhBrian ritchieShefali agarwalOnxeo sa euronextGustave roussyInstitut curieCompany groupRegulatory newsEuronext growth parisFirst north copenhagenChief executive officerInvus public equitiesEuronext paris

Onxeo SA (via Public) / Onxeo appoints Julien Miara as new interim CEO

Onxeo SA (via Public) / Onxeo appoints Julien Miara as new interim CEO
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

France generalShefali agarwalOnxeo sa euronextJulien miaraEuronext growth parisFirst north copenhagenChief executive officerInvus public equities

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. , a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and. | December 12, 2021

United statesShefali agarwalConnie lee batleviAmerican society of hematologyCelgene corporationBristol myers squibbEpizyme incMemorial sloan kettering cancer centerMemorial sloan kettering cancerOverall responseResponse rateExecutive vice presidentChief medicalDevelopment officerPrescribing informationNc stock exchange

Onxeo S A : Onxeo Continues to Strengthen its Board of Directors

Bryan Giraudo, COO CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company's Board as independent member Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First

United statesFrance generalNicolas merigeauJudith grecietEmmanuel huynhShefali agarwalValerie leroyOnxeo sa euronextBryan giraudoThomas hofstaetterCompany boardMerrill lynch global healthcare investment banking divisionCompany groupGossamer bioEuronext growth parisNasdaq first north